|
Orthologous residues
|
|
MRLC2 (human): S2‑p, MRLC2 (mouse): S2‑p, MRLC2 (rat): S2‑p, MRLC2 (cow): S2‑p
|
|
Characterization
|
|
Methods used to characterize site in vivo:
mutation of modification site, phospho-antibody, western blotting
|
|
Relevant cell lines - cell types - tissues:
3T3 (fibroblast)
|
|
Cellular systems studied:
cell lines
|
|
Species studied:
mouse
|
|
Enzymes shown to modify site in vitro:
|
|
|
|
Upstream Regulation
|
|
Treatments, proteins and their effect on site modification:
|
|
Treatments
|
Referenced Treatments
|
Manipulated Protein
|
Referenced Protein
|
Effect
|
Notes
|
|
PDGF
|
|
|
|
increase
|
|
|
GF109203X
|
PDGF
|
|
|
inhibit treatment-induced increase
|
|
|
LY294002
|
PDGF
|
|
|
no effect upon treatment-induced increase
|
|
|
PD98059
|
PDGF
|
|
|
no effect upon treatment-induced increase
|
|
|
SB203580
|
PDGF
|
|
|
no effect upon treatment-induced increase
|
|
|
Go 6976
|
PDGF
|
|
|
inhibit treatment-induced increase
|
|
|
rottlerin
|
PDGF
|
|
|
no effect upon treatment-induced increase
|
|
|
|
Downstream Regulation
|
|
Effect of modification (process):
cell adhesion, altered, cytoskeletal reorganization
|
|
Comments:
induced disassembly of stress fibers and decreased large focal adhesions
|